dc.contributor.author | Calvo Río, Vanesa | es_ES |
dc.contributor.author | Hernández Hernández, José Luis | es_ES |
dc.contributor.author | Ortiz Sanjuán, Francisco | es_ES |
dc.contributor.author | Loricera García, Javier | es_ES |
dc.contributor.author | Palmou Fontana, Natalia | es_ES |
dc.contributor.author | González Vela, María del Carmen | es_ES |
dc.contributor.author | González-Lamuño Leguina, Domingo | es_ES |
dc.contributor.author | González López, Marcos Antonio | es_ES |
dc.contributor.author | Armesto Alonso, Susana | es_ES |
dc.contributor.author | Blanco Alonso, Ricardo | es_ES |
dc.contributor.author | González-Gay Mantecón, Miguel Ángel | es_ES |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2017-07-10T09:23:26Z | |
dc.date.available | 2017-07-10T09:23:26Z | |
dc.date.issued | 2016 | es_ES |
dc.identifier.issn | 0025-7974 | es_ES |
dc.identifier.issn | 1536-5964 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10902/11356 | |
dc.description.abstract | To further investigate into the relapses of Henoch?Schönlein purpura (HSP), we analyzed the frequency, clinical features, and predictors of relapses in series of 417 unselected patients from a single center. After a median follow-up of 12 (interquartile range [IQR]: 2?38) years, almost one-third of the 417 patients (n=133; 32%; 85men/48 women) had experienced at least 1 relapse. At the time of disease diagnosis, patients who later experienced relapses had less commonly infections than those who never suffered flares (30.8% vs 41.9%; P=0.03). In contrast, patients who experienced relapses had a longer duration of the first episode of palpable purpura than those without relapses (palpable purpura lasting >7 days; 80.0% vs 68.1%; P=0.04). Abdominal pain (72.3% vs 62.3%; P=0.03) and joint manifestations (27.8% vs 15.5%; P=0.005) were also more common in patients who later developed relapses. In contrast, patients who never suffered relapses had a slightly higher frequency of fever at the time of disease diagnosis (9.3% vs 3.8%; P=0.06). At the time of disease diagnosis, corticosteroids were more frequently given to patients who later had relapses of the disease (44% vs 32% in nonrelapsing patients; P=0.03). Relapses generally occurred soon after the first episode of vasculitis. The median time from the diagnosis of HSP to the first relapse was 1 (IQR: 1?2) month. The median number of relapses was 1 (IQR 1?3). The main clinical features at the time of the relapse were cutaneous (88.7%), gastrointestinal (27.1%), renal (24.8%), and joint (16.5%) manifestations. After a mean±standard deviation follow-up of 18.9±9.8 years, complete recovery was observed in 110 (82.7%) of the 133 patients who had relapses. Renal sequelae (persistent renal involvement) was found in 11 (8.3%) of the patients with relapses. The best predictive factors for relapse were joint and gastrointestinal manifestations at HSP diagnosis (odds ratio [OR]: 2.22; 95% confidence interval [CI]: 1.34?3.69, and OR: 1.60; 95% CI: 1.01?2.53, respectively). In contrast, a history of previous infection was a protective factor for relapses (OR: 0.60; 95% CI: 0.38?0.94). In conclusion, joint and gastrointestinal manifestations at the time of diagnosis of HSP are predictors of relapses. | es_ES |
dc.format.extent | 8 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Lippincott Williams & Wilkins | es_ES |
dc.rights | Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND). | es_ES |
dc.source | Medicine (Baltimore). 2016 Jul;95(28):e4217 | es_ES |
dc.title | Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.1097/MD.0000000000004217 | es_ES |
dc.type.version | publishedVersion | es_ES |